Clinical trial
Pilot Study of Crizotinib in Relapsed ALK+ Lymphomas
NCT02419287 is registered in ClinicalTrials.gov with University of Milano Bicocca as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Pilot Study of Crizotinib in Relapsed ALK+ Lymphomas
- Lead sponsor
- University of Milano Bicocca
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- April 30, 2015
- Completion date
- December 31, 2022
- Enrollment
- 12 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
anaplastic large cell lymphoma, alk-positive